Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.01:25

Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.

Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
Chronic Obstructive Pulmonary Disease01:24

Chronic Obstructive Pulmonary Disease

COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Chronic Obstructive Pulmonary Disease I: Introduction01:23

Chronic Obstructive Pulmonary Disease I: Introduction

Chronic obstructive pulmonary disease is a common, preventable, and treatable respiratory disorder characterized by persistent symptoms and progressive airflow limitation. This limitation results from a combination of small-airway disease (obstructive bronchiolitis) and parenchymal destruction (emphysema), both driven by chronic inflammation from exposure to harmful particles or gases.The disease includes two main pathological entities: emphysema, marked by destruction of alveolar walls and...
Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features01:24

Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features

Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...
Chronic Obstructive Pulmonary Disease-I: Introduction01:20

Chronic Obstructive Pulmonary Disease-I: Introduction

Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Visceral adipose tissue: A relevant inflammatory compartment in obesity-related asthma?

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology·2023
Same author

Bronchodilator Reversibility in the GAN Severe Asthma Cohort.

Journal of investigational allergology & clinical immunology·2022
Same author

[The Current Therapy of Asbestos-Associated Malignant Pleural Mesothelioma - An Expert Consensus Paper].

Pneumologie (Stuttgart, Germany)·2021
Same author

[Guideline for the Diagnosis and Treatment of Asthma - Addendum 2020 - Guideline of the German Respiratory Society and the German Atemwegsliga in Cooperation with the Paediatric Respiratory Society and the Austrian Society of Pneumology].

Pneumologie (Stuttgart, Germany)·2021
Same author

[COVID-19 Vaccination in Asthma Patients Treated with Biologicals - Statement of the Austrian Society of Pneumology and German Respiratory Society].

Pneumologie (Stuttgart, Germany)·2021
Same author

[Congenital Pulmonary Artery Stenoses as a Rare Cause of Pulmonary Hypertension].

Pneumologie (Stuttgart, Germany)·2021
Same journal

Pneumologie (Stuttgart, Germany)·2026
Same journal

Aerosol therapy during noninvasive ventilation (NIV) and nasal high-flow therapy (HFT): current technology and consensus-based recommendations.

Pneumologie (Stuttgart, Germany)·2026
Same journal

[Correction: Pharmacotherapy for Tobacco Dependence: Implementation of the Current G-BA Resolution - Erratum: Information from Section E3 of the DGP regarding the G-BA Resolution].

Pneumologie (Stuttgart, Germany)·2026
Same journal

[Pharmacotherapy for Tobacco Dependence: Implementation of the Current G-BA Resolution - Information from Section E3 of the DGP regarding the G-BA Resolution].

Pneumologie (Stuttgart, Germany)·2026
Same journal

[Acute lung failure].

Pneumologie (Stuttgart, Germany)·2026
Same journal

[The internet as a source of information for patients with sarcoidosis].

Pneumologie (Stuttgart, Germany)·2026
See all related articles

Related Experiment Video

Updated: Jun 12, 2026

Studying Effects of Cigarette Smoke on Pseudomonas Infection in Lung Epithelial Cells
09:15

Studying Effects of Cigarette Smoke on Pseudomonas Infection in Lung Epithelial Cells

Published on: May 11, 2020

[COPD and infection].

R Bals1, A Gillissen, J Lorenz

  • 1Klinik für Innere Medizin, Schwerpunkt Pneumologie, Universität Marburg.

Pneumologie (Stuttgart, Germany)
|June 10, 2010
PubMed
Summary
This summary is machine-generated.

Infections frequently trigger exacerbations in patients with chronic obstructive pulmonary disease (COPD). Understanding these triggers and optimizing antibiotic use can improve patient outcomes and reduce mortality risks.

More Related Videos

Alternative Therapy for Acute Exacerbation of Chronic Obstructive Pulmonary Disease: Moving Cupping Along Meridians
04:03

Alternative Therapy for Acute Exacerbation of Chronic Obstructive Pulmonary Disease: Moving Cupping Along Meridians

Published on: September 27, 2024

Related Experiment Videos

Last Updated: Jun 12, 2026

Studying Effects of Cigarette Smoke on Pseudomonas Infection in Lung Epithelial Cells
09:15

Studying Effects of Cigarette Smoke on Pseudomonas Infection in Lung Epithelial Cells

Published on: May 11, 2020

Alternative Therapy for Acute Exacerbation of Chronic Obstructive Pulmonary Disease: Moving Cupping Along Meridians
04:03

Alternative Therapy for Acute Exacerbation of Chronic Obstructive Pulmonary Disease: Moving Cupping Along Meridians

Published on: September 27, 2024

Area of Science:

  • Pulmonology
  • Infectious Diseases
  • Immunology

Background:

  • Chronic obstructive pulmonary disease (COPD) exacerbations are often caused by infections.
  • A complex interplay exists between COPD, comorbidities, physical inactivity, and systemic inflammation.
  • The pathogenesis of infections in COPD involves both adaptive and innate immune systems.

Framework:

  • Differentiating between bacterial colonization and true infection is crucial for appropriate treatment.
  • The precise role of viral infections in COPD exacerbations requires further investigation, including distinguishing acute infection from viral persistence.
  • Community-acquired pneumonia presents a significant risk to COPD patients.

Implementation:

  • Clinical scores and procalcitonin levels aid in antibiotic treatment decisions.
  • Short-course antibiotic therapy (around 5 days) is likely sufficient, as longer durations do not increase efficacy but raise adverse event frequency.
  • Hospitalization for respiratory exacerbations is linked to increased mortality in COPD patients.

Implications:

  • Further research is needed to fully elucidate the chronic inflammatory systemic syndrome in COPD.
  • Identifying the role of physical inactivity as a common denominator in COPD pathogenesis is important.
  • Optimizing infection management strategies can potentially reduce COPD exacerbation frequency and severity, leading to improved patient prognosis and reduced healthcare burden.